{"disease":{"id":"age-related-macular-degeneration-armd","name":"age related macular degeneration armd"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06583109","title":"Prediction Model of Treatment Efficacy for Age-related Macular Degeneration Based on Multi-source Imaging Modalities","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2600,"lead_sponsor_name":"Beijing Hospital","has_results":false},{"nct_id":"NCT05735730","title":"Can the Risk for AMD be Modulated?","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1800,"lead_sponsor_name":"Association for Innovation and Biomedical Research on Light and Image","has_results":false},{"nct_id":"NCT04667039","title":"Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":408,"lead_sponsor_name":"AO GENERIUM","has_results":false},{"nct_id":"NCT07514559","title":"Comparison of Intravitreal Anti-VEGF Treatment Burden in Different Retinal Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":393,"lead_sponsor_name":"Hospital Hietzing","has_results":false},{"nct_id":"NCT01499628","title":"EFFECT:Eccentric Fixation From Enhanced Clinical Training","phase":"NA","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Moorfields Eye Hospital NHS Foundation Trust","has_results":false},{"nct_id":"NCT06662162","title":"Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"i-Lumen Scientific AUS PTY LTD","has_results":false},{"nct_id":"NCT06683950","title":"Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Kim's Eye Hospital","has_results":false},{"nct_id":"NCT07187804","title":"Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Kim's Eye Hospital","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}